The study supports prior research that found the same thing.

Ozempic is not marketed as a weight loss drug and is prescribed to those with type 2 diabetes to help manage their condition ...

A new study suggests that two widely used Type 2 diabetes medications—GLP-1 receptor agonists and SGLT2 inhibitors—may help reduce the risk of Alzheimer’s disease and related dementias.

GLP-1 and SGLT2 drugs — could significantly reduce the risk of developing dementia in life, a large new study has found.

New research suggests that GLP-1 drugs like Ozempic and Wegovy, commonly used for diabetes and weight loss, may also reduce the risk of Alzheimer's disease and dementia.

A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type ...

Two studies suggested the diabetes/weight-loss drug may have a beneficial side effect—but more work is needed to confirm this.

Medications designed to treat diabetes by lowering blood sugar levels, like Ozempic, continue to turn up added benefits, and ...

1:54 GLP-1 drugs like Ozempic, Wegovy reduce Alzheimer’s risk for those with diabetes Two major studies published Monday in JAMA Neurology found that GLP-1 medications are linked to a lower risk ...

None had been diagnosed with Alzheimer disease and related dementias at the start of the study. The researchers discovered that people who took GLP-1 receptor agonists (like Ozempic) or a type of ...

Dozens of trials testing GLP-1 drugs like semaglutide, the medicine in Ozempic and Wegovy, against a placebo suggest that ...

Semaglutide — the powerful ingredient behind Wegovy and Ozempic — has long been hailed ... seems to be promising in reducing the risk of Alzheimer's disease and related dementias (ADRD)'.